331647-05-3

Basic information

• Product Name: 8-BROMO-2,4-DICHLOROQUINAZOLINE
• Synonyms: 2,4-DICHLORO-8-BROMOQUINAZOLINE;8-BROMO-2,4-DICHLOROQUINAZOLINE;Quinazoline, 8-bromo-2,4-dichloro-
• CAS NO: 331647-05-3
• Molecular Formula: C8H3BrCl2N2
• Molecular Weight: 277.936
• Mol File: 331647-05-3.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 248.2 °C at 760 mmHg
• Flash Point: 103.9 °C
• Appearance: /
• Density: 1.851
• Vapor Pressure: 0.0388mmHg at 25°C
• Refractive Index: 1.696
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.75±0.30(Predicted)
• CAS DataBase Reference: 8-BROMO-2,4-DICHLOROQUINAZOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 8-BROMO-2,4-DICHLOROQUINAZOLINE(331647-05-3)
• EPA Substance Registry System: 8-BROMO-2,4-DICHLOROQUINAZOLINE(331647-05-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 331647-05-3(Hazardous Substances Data)

Usage

General Description

8-Bromo-2,4-dichloroquinazoline is a chemical compound that belongs to the class of quinazoline derivatives. It is a highly reactive compound with two chlorine atoms and one bromine atom attached to a quinazoline ring. 8-BROMO-2,4-DICHLOROQUINAZOLINE has potential applications in various fields including pharmaceuticals, agrochemicals, and material sciences. It is often used as a building block in the synthesis of more complex molecules and is also studied for its potential pharmacological properties. The presence of halogen atoms in its structure makes it an attractive candidate for further chemical modifications to enhance its biological activity and selectivity. Its unique structure and reactivity make 8-Bromo-2,4-dichloroquinazoline an important compound in the field of organic chemistry and drug discovery.

InChI:InChI=1/C8H3BrCl2N2/c9-5-3-1-2-4-6(5)12-8(11)13-7(4)10/h1-3H

Upstream product

• 331646-99-2 8-bromoquinazoline-2,4-(1H,3H)-dione 
• 608-30-0 2,6-dibromoaniline 
• 114344-60-4 2-amino-3-bromo-benzonitrile 
• 20776-51-6 2-amino-3-bromo benzoic acid 
• 331646-99-2 8-bromoquinazoline-2,4-diol 

Downstream Products

• 956100-62-2 8-bromo-2-chloroquinazolin-4-amine 

Relevant articles and documents

CD73 INHIBITORS

Disclosed are compounds that are inhibitors of CD73 and are useful in treating CD73-associated diseases or conditions, and compositions containing the compounds.

Discovery of (R)-8-(6-Methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4- b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)quinazolin-4(3 H)-one, a Potent and Selective Pim-1/2 Kinase Inhibitor for Hematological Malignancies

Pim kinases are a family of constitutively active serine/threonine kinases that are partially redundant and regulate multiple pathways important for cell growth and survival. In human disease, high expression of the three Pim isoforms has been implicated in the progression of hematopoietic and solid tumor cancers, which suggests that Pim kinase inhibitors could provide patients with therapeutic benefit. Herein, we describe the structure-guided optimization of a series of quinazolinone-pyrrolodihydropyrrolone analogs leading to the identification of potent pan-Pim inhibitor 28 with improved potency, solubility, and drug-like properties. Compound 28 demonstrated on-target Pim activity in an in vivo pharmacodynamic assay with significant inhibition of BAD phosphorylation in KMS-12-BM multiple myeloma tumors for 16 h postdose. In a 2-week mouse xenograft model, daily dosing of compound 28 resulted in 33% tumor regression at 100 mg/kg.

FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF

Disclosed area fused ring pyrimidine compound, and an intermediate, a preparation method, a composition and a use thereof. The fused ring pyrimidine compound is a compound as shown in formula I, a tautomer, an enantiomer, a diastereoisomer, a pharmaceutically acceptable salt, a metabolite, a metabolic precursor or a prodrug thereof, wherein the above-mentioned compound is used for the preparation of a medicine for preventing, remitting or treating one or more of immune system diseases, autoimmune diseases, cell proliferative diseases, allergic disorders and cardiovascular diseases, and the compound has a strong inhibitory effect on the Janues kinase, FGFR kinase, FLT3 kinase and Src family kinase.